We prospectively treated patients with hepatitis C virus (HCV)-associated indolent lymphomas with genotype-appropriate direct-acting antivirals (DAAs) with the aim to evaluate virologic and hematologic outcomes. No prospective studies in this setting have been published so far.
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi / Merli, M., Rattotti, S., Spina, M., Re, F., Motta, M., Piazza, F., Orsucci, L., Ferreri, A.J.M., Perbellini, O., Dodero, A., Vallisa, D., Pulsoni, A., Santoro, A., Sacchi, P., Zuccaro, V., Chimienti, E., Russo, F., Visco, C., Zignego, A.L., Marcheselli, L., et al.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 40:(2022), pp. 4060-4070. [10.1200/JCO.22.00668]
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi
Zignego, Anna LindaInvestigation
;
2022
Abstract
We prospectively treated patients with hepatitis C virus (HCV)-associated indolent lymphomas with genotype-appropriate direct-acting antivirals (DAAs) with the aim to evaluate virologic and hematologic outcomes. No prospective studies in this setting have been published so far.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jco-40-4060.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
419.43 kB
Formato
Adobe PDF
|
419.43 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
